Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Sourij, C; Obermayer, A; Sourij, H.
SGLT-inhibitors as a therapeutic option for patients with type 1 diabetes
AUST J CLIN ENDOCR M. 2018; 11(4): 122-126.
Doi: 10.1007/s41969-018-0050-7
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Sourij Caren
- Sourij Harald
- Co-authors Med Uni Graz
- Ramirez-Obermayer Anna Maria Antonia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- While insulin therapy is vital for subjects with type 1 diabetes, supporting glucose lowering agents are needed, helping to optimize glycaemic control while not increasing hypoglycaemia risk. Sodium glucose co-transporter (SGLT)-inhibitors are lowering blood glucose by increasing glucosuria, a mechanism also working in type 1 diabetes. This review summarizes current efficacy data of SGLT-inhibitors in type 1 diabetes and discusses the increased risk for euglycaemic ketoacidosis associated with this drug class.
- Find related publications in this database (Keywords)
- Dapaglifozin
- Empaglifozin
- Insulin
- Ketoazidose
- Sotaglifozin
- Dapaglifozin
- Empaglifozin
- Insulin
- Ketoacidosis
- Sotaglifozin